The diagnosis and treatment of non-IPF progressive pulmonary fibrosis is a complex process that requires a combination of patient clinical performance, secondary examination results and individual circumstances. The following is a detailed description of their diagnosis and treatment:
I. Diagnosis
Clinical manifestations of non-IPF progressive pulmonary fibrosis may show persistent symptoms such as cough, sexual respiratory difficulties (not visible after the activity), stifling fingers/toes. Some of these patients may be associated with non-specific overall symptoms such as appetite loss, weight loss and inactivity. Auxiliary examination of chest high resolution CT (HRCT): is an important means of diagnosing lung fibrosis. The HRCT is able to clearly distinguish the internal structure of the lungs and can help to detect fibrosis in the lungs, such as grids, beehives, grinding glass. Pulmonary function examination: includes indicators such as hard lung activity (FVC), total lung (TCL) and carbon monoxide (DLco). Non-IPF progressive pulmonary fibrosis patients usually suffer from restricted ventilation and dispersive functional disorders. Serobiology markers: KL-6, CC16, etc., are likely to be significantly higher in pulmonary fibrosis patients, which can assist in supporting diagnosis. It needs to be noted, however, that the specificity of these markers may be low and require a comprehensive assessment in conjunction with other inspections. BALF: Although the diagnosis and prognosis of pulmonary fibrosis in cytology remains widely contested, it remains an important means of identifying diagnostics. BALF examinations allow for the detection of bronchial cavity and help to identify diseases such as lung infections, allergies and tumours. Pulmonary biopsy: There is a certain risk for creative examinations. However, when a visual examination does not determine the type of disease or the patient ‘ s condition is not extreme, a pulmonary biopsy may help to identify the pathology type, understand the pulmonary stress and make a prognosis. However, pulmonary active examinations are not necessary for all pulmonary fibrosis patients and are subject to decision-making on the basis of the patient ‘ s particular circumstances and the doctor ‘ s advice. Multidisciplinary discussions (MDTs) are conducted to develop individualized diagnostic programmes, taking into account the clinical performance of patients, the results of supplementary examinations and the individual situation. Exclusion of other pulmonary diseases that may cause similar symptoms, such as ad hoc pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD).
Treatment
The general treatment is to stop smoking and alcohol and to avoid inhalation of harmful gases and particles. A balanced diet with a clean and clean indoor air. Appropriate pulmonary rehabilitation treatment, such as respiration, aerobics, etc., to improve the function and quality of life of patients. Drugs for sugar cortex hormones, such as disemison and methyl-strength pine dragons, are used to control inflammation and reduce fibrosis. However, long-term use can have a range of side effects, such as hypertension, diabetes, etc., which need to be weighed against pros and cons. Immunosuppressants: e.g., cyclophosphate, sulfur, etc., are used to inhibit immune response and reduce fibrosis progress. However, there are also side effects and risks which need to be used under the direction of a doctor. Anti-fibrosis drugs: e.g., thaphneone, Nidanib, etc., have some anti-fibrosis effects, but the efficacy of treatment is uncertain and expensive. Oxygen therapy for low-oxygen haemorrhagic patients, with long-term home-based Oxygen therapy, helps improve quality of life and preparation. Pulmonary transplants may be considered for patients with severe medical conditions and medically ineffective treatment. However, pulmonary transplant surgery is risky and expensive and requires long-term immunosuppressants to prevent exclusion. Treatment is provided for symptoms such as cough, cough, etc. of patients, such as the use of cough, sepsis, etc.
III. FOLLOW-UP AND MONITORING
Periodic follow-up visits are carried out to assess the progress of the condition and the effectiveness of the treatment by means of supplementary examinations such as chest CT and lung function examinations. Treatment programmes are adapted to the situation to ensure maximum effectiveness. The monitoring of complications follows up on possible complications such as pulmonary artery pressure, respiratory failure, etc., and takes appropriate treatment measures.
In the light of the above, the diagnosis and treatment of non-IPF progressive pulmonary fibrosis requires a combination of clinical performance of the patient, the results of supplementary examinations and the individual situation. Early diagnosis and active treatment can slow progress and improve the quality of life of patients. At the same time, patients are required to actively cooperate with the doctor ‘ s recommendations for treatment, and to conduct regular follow-up and management.
